Product image of Leuprorelin Sandoz (Leuprorelin) supplied by GNH India

Leuprorelin Sandoz

Active Ingredient:
Leuprorelin
Origin:
EU

Leuprorelin Sandoz (Leuprorelin)

Leuprorelin, the active ingredient in Leuprorelin Sandoz, is a Gonadotropin‑releasing hormone (GnRH) agonist presented as a sterile injectable solution for subcutaneous use. It suppresses sex hormone production and is employed in the management of hormone‑dependent cancers and benign gynecological conditions in adults.

GNH India supplies Leuprorelin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sandoz Pharmaceuticals D.D.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Leuprorelin is a GnRH agonist used in several hormone‑dependent conditions.

  • Prostate cancer: lowers testosterone levels to help control tumor growth.
  • Endometriosis: reduces estrogen stimulation of ectopic endometrial tissue, alleviating pain.
  • Uterine fibroids: diminishes fibroid size by suppressing ovarian hormone production.
  • Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis.
  • Breast cancer (adjuvant therapy): decreases circulating estrogen to support other systemic treatments.

How It Works

  • Leuprorelin is a synthetic GnRH agonist that initially stimulates pituitary GnRH receptors, causing a transient rise in luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). Continued exposure leads to receptor down‑regulation, markedly reducing LH and FSH secretion and consequently suppressing downstream sex hormone (testosterone and estradiol) production.

Side Effects

Leuprorelin may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth, often with sweating.
  • Injection site reactions: pain, redness, or swelling at the subcutaneous site.
  • Headache: mild to moderate intensity.
  • Fatigue: general tiredness without exertion.
  • Nausea: occasional upset stomach.
  • Decreased libido: reduced sexual desire.

Serious or Rare Side Effects

  • Bone mineral density loss: increased risk of fractures with long‑term therapy.
  • Cardiovascular events: rare cases of myocardial infarction or stroke.
  • Severe allergic reaction: anaphylaxis, angioedema, or rash.
  • Pituitary apoplexy: sudden hemorrhage or infarction of the pituitary gland (extremely rare).

Precautions & Warnings

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly.

  • Monitor hormone levels: check testosterone or estradiol periodically to confirm suppression.
  • Assess bone health: consider calcium, vitamin D supplementation and bone density testing for long‑term use.
  • Screen cardiovascular risk: evaluate blood pressure, lipid profile, and smoking status.
  • Use caution in hepatic impairment: adjust monitoring as liver function may affect drug handling.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Leuprorelin can interact with other medicines that influence hormonal pathways or cardiovascular risk.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase systemic exposure.
  • Estrogen‑containing contraceptives: can reduce the intended hormonal suppression.
  • Anticoagulants (e.g., warfarin): hormonal changes may alter coagulation status.

Moderate Interactions (Monitor Closely)

  • Bisphosphonates: concurrent use may affect bone turnover monitoring.
  • Glucocorticoids: may exacerbate bone loss when combined with hormone suppression.
  • Thyroid hormone replacement: hormonal shifts can influence thyroid function tests.

Frequently Asked Questions

Leuprorelin Sandoz is a GnRH agonist indicated for the treatment of hormone‑dependent conditions such as prostate cancer, endometriosis, uterine fibroids, precocious puberty, and as an adjuvant in certain breast cancer regimens. It works by suppressing the production of sex hormones that drive disease progression.

Leuprorelin mimics natural GnRH, initially stimulating the pituitary gland before causing receptor down‑regulation. This leads to a sustained fall in luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), which in turn sharply reduces testosterone and estradiol levels, limiting hormone‑driven disease activity.

The dosage and administration schedule for Leuprorelin Sandoz are determined by the prescribing clinician based on the specific indication, patient characteristics, and treatment goals. Healthcare professionals select the appropriate strength, frequency and duration according to approved labeling and clinical guidelines.

Leuprorelin is generally contraindicated during pregnancy because it suppresses sex hormone production essential for fetal development. Limited data exist for breastfeeding, and the drug may be excreted in milk; therefore, use is not recommended unless the potential benefit justifies the risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Leuprorelin belongs to the same class as goserelin, triptorelin and histrelin. All provide potent gonadotropin suppression, but they differ in formulation, dosing intervals and manufacturer. Choice among them often depends on approved indications, patient convenience, cost considerations and local regulatory status.

Leuprorelin Sandoz should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and avoid exposing it to temperatures outside the recommended range to maintain potency.

Leuprorelin is given as a subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to reduce local irritation. Administration is performed by a qualified healthcare professional according to the prescribed schedule, which may range from monthly to quarterly dosing.

Serious risks include significant loss of bone mineral density leading to fractures, rare cardiovascular events such as myocardial infarction or stroke, and severe allergic reactions including anaphylaxis. Patients should be monitored for signs of these complications, especially during long‑term therapy.

Leuprorelin is contraindicated in individuals with known hypersensitivity to leuprorelin or any excipients, in patients with uncontrolled cardiovascular disease, and in women who are pregnant or planning pregnancy. Caution is also advised for patients with severe liver impairment or existing osteoporosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Leuprorelin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT